Erik Harris

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Redwood City, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Karah Parschauer, attorney-in-fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Erik Harris

Form 4 holding Director

Denali Therapeutics Inc.

Security class
Common Stock
Shares / value
17,052
Estimated value
$347,690
Report date
31 May 2024
Price
$20.39
Ownership
Direct
Form 4 holding Director

Inozyme Pharma, Inc.

Security class
Stock Option (right to buy)
Shares / value
56,000
Estimated value
Report date
03 Oct 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Denali Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
17,901
Estimated value
Report date
31 May 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Rezolute, Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
12,000
Estimated value
Report date
19 Nov 2025
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount

Insider Reports Filed by Erik Harris

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .